Petranel Ferrao

Summary

Affiliation: Peter MacCallum Cancer Centre
Location: Melbourne, Australia

Publications

  1. doi request reprint Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT
    R Foster
    School of Biomedical Sciences, The University of Newcastle, Callaghan, New South Wales 2308, Australia
    Br J Dermatol 159:1160-9. 2008
  2. ncbi request reprint Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase
    Rowan Foster
    School of Biomedical Sciences, Faculty of Health, University of Newcastle, Callaghan NSW 2308, Australia
    J Mol Graph Model 23:139-52. 2004
  3. ncbi request reprint Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro
    Petranel T Ferrao
    Rm 511, Medical Sciences Bldg, University of Newcastle, University Dr, Callaghan, New South Wales 2308, Australia
    Blood 102:4499-503. 2003
  4. ncbi request reprint Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver
    Petranel T Ferrao
    School of Biomedical Sciences, Faculty of Health, University of Newcastle, Room 511, Medical Sciences Building, University Drive, Callaghan 2308, Australia
    Leuk Res 27:547-55. 2003
  5. ncbi request reprint Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant
    Michelle J Frost
    School of Biomedical Sciences, University of Newcastle, Room 511, Medical Sciences Building, Callaghan, NSW 2308, Australia
    Mol Cancer Ther 1:1115-24. 2002
  6. ncbi request reprint Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
    R Chian
    Basic Research Laboratory and the Laboratory of Immunobiology, Division of Basic Sciences, National Cancer Institute-Frederick, MD 21702, USA
    Blood 98:1365-73. 2001
  7. ncbi request reprint Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia
    P Ferrao
    Division of Haematology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, PO Box 14 Rundle Mall, Frome Road, Adelaide, SA 5000, Australia
    Leuk Res 25:395-405. 2001
  8. ncbi request reprint Effects of mutant c-kit in early myeloid cells
    L K Ashman
    Division of Haematology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, Australia
    Leuk Lymphoma 37:233-43. 2000
  9. doi request reprint Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
    P T Ferrao
    Molecular Oncology Laboratory and Cancer Therapeutics Program, Research Division, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia
    Oncogene 31:1661-72. 2012

Collaborators

Detail Information

Publications13

  1. doi request reprint Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT
    R Foster
    School of Biomedical Sciences, The University of Newcastle, Callaghan, New South Wales 2308, Australia
    Br J Dermatol 159:1160-9. 2008
    ..The receptor tyrosine kinase c-KIT plays a key role in normal mast cell development. Point mutations in c-KIT have been associated with sporadic or familial mastocytosis...
  2. ncbi request reprint Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase
    Rowan Foster
    School of Biomedical Sciences, Faculty of Health, University of Newcastle, Callaghan NSW 2308, Australia
    J Mol Graph Model 23:139-52. 2004
    ..The reasons for this apparent discrepancy are discussed...
  3. ncbi request reprint Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro
    Petranel T Ferrao
    Rm 511, Medical Sciences Bldg, University of Newcastle, University Dr, Callaghan, New South Wales 2308, Australia
    Blood 102:4499-503. 2003
    ..In contrast, overexpression of Bcl-xL, which blocks apoptosis, resulted in partial protection against the drug. We conclude that Pgp up-regulation is not likely to be a significant contributor to imatinib resistance...
  4. ncbi request reprint Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver
    Petranel T Ferrao
    School of Biomedical Sciences, Faculty of Health, University of Newcastle, Room 511, Medical Sciences Building, University Drive, Callaghan 2308, Australia
    Leuk Res 27:547-55. 2003
    ..We conclude that constitutive expression of D816VKit in primary haemopoietic cells is not a sufficient transforming stimulus but leads to the survival and maturation of cells whose phenotype is influenced by the presence of SCF...
  5. ncbi request reprint Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant
    Michelle J Frost
    School of Biomedical Sciences, University of Newcastle, Room 511, Medical Sciences Building, Callaghan, NSW 2308, Australia
    Mol Cancer Ther 1:1115-24. 2002
    ..Overall, these findings demonstrate the increased susceptibility of the Kit juxtamembrane mutant, V560G, and the resistance of the kinase domain mutant, D816V, to Imatinib compared with WTKit...
  6. ncbi request reprint Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
    R Chian
    Basic Research Laboratory and the Laboratory of Immunobiology, Division of Basic Sciences, National Cancer Institute-Frederick, MD 21702, USA
    Blood 98:1365-73. 2001
    ....
  7. ncbi request reprint Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia
    P Ferrao
    Division of Haematology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, PO Box 14 Rundle Mall, Frome Road, Adelaide, SA 5000, Australia
    Leuk Res 25:395-405. 2001
    ..Therefore, the level of total P-gp protein or mRNA may be a better indicator of MDR than surface P-gp protein. In addition, we provide evidence for a novel mechanism of drug sequestration in K562 myeloid leukaemic cells...
  8. ncbi request reprint Effects of mutant c-kit in early myeloid cells
    L K Ashman
    Division of Haematology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, Australia
    Leuk Lymphoma 37:233-43. 2000
    ..Thus the extent to which c-Kit mutations contribute to malignancies of early myeloid phenotype remains unknown, and resolution of this issue is complicated by the heterogeneity of this family of diseases...
  9. doi request reprint Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
    P T Ferrao
    Molecular Oncology Laboratory and Cancer Therapeutics Program, Research Division, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia
    Oncogene 31:1661-72. 2012
    ..We propose that inhibitors of CHK can act in a synthetically lethal manner in cancers with replication stress as a result of these cancers being reliant on CHK proteins for an effective DDR and cell survival...